Date: 2015-03-27
Type of information: Licensing agreement
Compound: sd-rxRNA® technology for use in developing innovative cell-based cancer immunotherapies
Company: RXi Pharmaceuticals (USA - MA) MirImmune (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: RNAi/antisense oligonucleotide. RXi\'s self-delivering RNAi (sd-rxRNA) compounds are hybrid oligonucleotide molecules that combine the beneficial properties of both conventional RNAi and antisense technologies. The sd-rxRNAs have a single-stranded phosphorothioate region, a short duplex region, and contain a variety of nuclease-stabilizing and lipophilic chemical modifications.
Disease:
Details:
* On March 27, 2015, RXi Pharmaceuticals and privately-held MirImmune announced that they have entered into an exclusive license agreement to RXi\'s novel and proprietary sd-rxRNA® technology for use in developing innovative cell-based cancer immunotherapies. The collaboration has the potential to result in novel, more effective and patient friendly cancer treatments that could be a significant step toward personalized medicine. Under the terms of the agreement, MirImmune will be responsible for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. It will develop cell-based therapeutics utilizing RXi\'s sd-rxRNA technology to target immune checkpoints which are responsible for limiting the efficacy of cancer immunotherapies. According to the terms, MirImmune will gain access to RXi\'s sd-rxRNA® and rxRNAori® patent families for ex vivo modification of cells for the treatment of cancer. These patents include the composition of the sd-rxRNA and rxRNAori RNAi structures, as well as potential targets for cell-based therapeutics.
Financial terms: As consideration for this license, RXi will receive an annual licensing fee, clinical milestone payments, sublicensing income and single digit royalties. Pending MirImmune\'s achievement of a few gating milestones, RXi will have the right to acquire a double-digit equity stake in MirImmune.
Latest news:
